ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

TMO EPM / Hemato H9J

Por: TMO EPM / Hemato H9J

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

65 episodios disponibles

Últimos episódios do podcast TMO EPM / Hemato H9J

Mostrando página 3 de 4

25 - PTCy versus ATG after RIC peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors 28/03/2024

24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study 25/03/2024

23 - Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up 16/03/2024

22 - Tacrolimus /methotrexate vs tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease prevention 03/03/2024

21 - Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids 29/02/2024

20 - Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML 17/02/2024

19 - Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study 04/02/2024

18 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma 29/01/2024

17 - Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease 14/01/2024

16 - Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML 17/12/2023

15 - Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation 03/12/2023

14 - BuFlu vs BuCy for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial 26/11/2023

13 - R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma 19/11/2023

12 - PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation 13/11/2023

11 - Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER) 22/10/2023

10 - Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma 08/10/2023

09 - Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis 02/10/2023

08 - Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL 24/09/2023

07 - Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients 28/08/2023

06 - Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma 19/08/2023

« Primera ‹ Anterior 1 2 3 4 Siguiente › Última »